CDK4 and neoplasm: Agents specifically targeting cyclin-dependent kinases 4 or 6 (cyclin-dependent kinases 4/6, CDK4/6) (palbociclib, ribociclib, etc.)have a high affinity for CDK4/6, which can lead to G1-phase cell cycle arrest and tumor growth inhibition [6, 7].